Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by BAP1 localizes to the nucleus and it interacts with the RING finger domain of the breast cancer 1, early onset protein (BRCA1).
Showing 10 out of 133 products:
Human Polyclonal BAP1 Primary Antibody for IHC (p), WB - ABIN388948
Abdel-Rahman, Pilarski, Cebulla, Massengill, Christopher, Boru, Hovland, Davidorf: Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. in Journal of medical genetics 2011
Human Monoclonal BAP1 Primary Antibody for FACS, WB - ABIN258775
Harbour, Onken, Roberson, Duan, Cao, Worley, Council, Matatall, Helms, Bowcock: Frequent mutation of BAP1 in metastasizing uveal melanomas. in Science (New York, N.Y.) 2010
A cancer surveillance program for individuals who carry germline BAP1 (show RNF2 Antibodies) mutations may help identify tumors such as uveal melanoma, cutaneous melanoma, and renal cell carcinoma (show MOK Antibodies) at early and treatable stages
Germline BAP1 (show RNF2 Antibodies) mutations induce a Warburg effect
Our comparative thermodynamic analysis reveals that BAP1-ubiquitin interaction is majorly driven by entropy factor which is unique amongst UCHs. Our study sheds light on BAP1 interaction with ubiquitin, which will be useful in understanding its enzymatic function.
Mutations in BAP1 (show RNF2 Antibodies) negatively affected overall survival in patients with metastatic clear cell renal cell carcinoma (show MOK Antibodies)
Our findings suggest that the genetic profile of coexistent GNAQ (show GNAQ Antibodies) or GNA11 (show GNA11 Antibodies) mutations with BAP1 (show RNF2 Antibodies) or SF3B1 (show SF3B2 Antibodies) mutations can aid the histopathological diagnosis of blue nevus-like melanoma and distinguish blue nevus-like melanoma from conventional epidermal-derived melanomas.
Intratumoral heterogeneity of BAP1 (show RNF2 Antibodies) protein expression is more frequent in primary tumor than in metastatic sites. The loss of BAP1 (show RNF2 Antibodies) protein expression in metastatic sites predicts poor prognosis in patients with ccRCC.
this review discusses BAP1 (show RNF2 Antibodies) as a drug target in mesothelioma
Loss of nuclear BAP1 (show RNF2 Antibodies) expression is an independent prognostic factor of poor overall survival and associated with distant metastasis in oral mucosal melanoma.
In malignant peritoneal mesothelioma, the most frequent genetic alteration was biallelic inactivation of the BAP1 (show RNF2 Antibodies) gene, which occurred in 9/13 cases, with an additional two cases demonstrating monoallelic loss of BAP1 (show RNF2 Antibodies). All 11 of these cases demonstrated loss of BAP1 (show RNF2 Antibodies) nuclear staining by immunohistochemistry
BAP1 (show RNF2 Antibodies) mutations and other canonical genomic aberrations usually arise in an early punctuated burst in uveal melanoma.
We conditionally targeted Bap1 and Pbrm1 (show PBRM1 Antibodies) (with Vhl (show VHL Antibodies)) in the mouse using several Cre drivers.Sglt2 and Villin proximal convoluted tubule drivers failed to cause tumorigenesis, challenging the conventional notion of Clear cell renal cell carcinoma (show MOK Antibodies) (ccRCC)origins
our results establish a previously unappreciated role of BAP1 in modulating the cellular adaptability to metabolic stress and uncover a pivotal function of BAP1 in the regulation of the ER stress gene-regulatory network.
dual inactivation of Vhl (show VHL Antibodies) with either Bap1 or Pbrm1 (show PBRM1 Antibodies) results in faithful genetically engineered murine models of clear cell renal cell carcinoma (show MOK Antibodies) (ccRCC).
Bap1 as a metabolic regulator in liver and pancreas.
BAP1(+/-) mice exposed to low-dose asbestos fibers showed an altered peritoneal inflammatory response and higher levels of pro-tumorigenic alternatively polarized M2 macrophages, and lower cytokine levels. They had a higher incidence of mesothelioma.
Bap1 loss led to a fully penetrant myeloproliferative disease with splenomegaly, leukocytosis, anemia and progenitor expansion via alterations in histone methylation and gene expression.
INO80 (show INO80 Antibodies) is stabilized and targeted to replication forks by BAP1 during normal DNA synthesis but downregulated in BAP1 defective cancer cells
Both Vhl (show VHL Antibodies) and Bap1 are required for kidney function. Inactivation of Bap1 in neprhon progenitor cells causes renal failure earlier than Vhl (show VHL Antibodies) inactivation. Bap1 is also a stronger tumor suppressor gene than Vhl (show VHL Antibodies) in the kidney.
Drawing parallels to human disease, these unbiased genetic findings indicate that BAP1 mutation carriers are predisposed to the tumorigenic effects of asbestos and suggest that high penetrance of mesothelioma requires such environmental exposure.
results identify a potent tumor suppressor function for BAP1 in myeloid neoplasia; propose that BAP1 forms a core complex with HCF-1 (show HCFC1 Antibodies) and OGT (show OGT Antibodies) that can differentially recruit additional histone-modifying enzymes to regulate gene expression and preserve norm
The protein encoded by this gene localizes to the nucleus and it interacts with the RING finger domain of the breast cancer 1, early onset protein (BRCA1). This gene is thought to be a tumor suppressor gene that functions in the BRCA1 growth control pathway. There are multiple polyadenylation sites found in this gene.
cerebral protein 6
, cerebral protein-13
, ubiquitin carboxyl-terminal hydrolase BAP1
, BAI1-associated protein 3
, BRCA1-associated protein 1
, ubiquitin carboxy-terminal hydrolase
, Brca1 associated protein 1
, ubiquitin C-terminal hydrolase X4
, BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)